Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
As the global aging population rises, finding effective interventions to improve aging health is crucial. Drug repurposing, utilizing existing drugs for new purposes, presents a promising strategy for rapid implementation. We explored naltrexone from the Library of Integrated Network-based Cellular Signatures (LINCS) based on several selection criteria. Low-dose naltrexone (LDN) has gained attention for treating various diseases, yet its impact on longevity remains underexplored. Our study on demonstrated that a low dose, but not high dose, of naltrexone extended the healthspan and lifespan. This effect was mediated through SKN-1 (NRF2 in mammals) signaling, influencing innate immune gene expression and upregulating oxidative stress responses. With LDN's low side effects profile, our findings underscore its potential as a geroprotector, suggesting further exploration for promoting healthy aging in humans is warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11126937 | PMC |
| http://dx.doi.org/10.1016/j.isci.2024.109949 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy and safety of low-dose naltrexone in the treatment of lichen planopilaris and frontal fibrosing alopecia: A systematic review.
J Am Acad Dermatol
September 2025
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada; Donovan Hair Clinic, Whistler, BC, Canada. Electronic address:
Co-administration of low-dose-Naltrexone and Carbamazepine remarkedly ameliorate allodynia and cognitive deficit in a rat model of trigeminal neuralgia.
Sci Rep
August 2025
Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.
The aim of this study was to examine the pain-relieving effects of combining Carbamazepine (CBZ) and low-dose-Naltrexone (LDN) in trigeminal neuralgia (TN) to reduce the side effects of CBZ and the potential of synergistic antiallodynic interaction. Male Wistar rats were allocated randomly to 8 groups: Control, Sham, TN, TN (CBZ 100 mg), TN (CBZ 100 mg oral (p.o.
View Article and Find Full Text PDFLow Dose Naltrexone for Refractory Cancer Pain: Case Series of Initial Safety and Effectiveness.
J Pain Symptom Manage
August 2025
Department of Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, United States. Electronic address:
Context: Low dose naltrexone (LDN) has been utilized off-label for chronic non-cancer pain; its benefits in treating cancer-related pain remain unclear.
Objectives: We describe the safety and effectiveness of LDN therapy from initiation to the first two follow-up visits in treating refractory cancer-pain.
Methods: Medical charts of cancer patients seen in the Pain Management Center who were prescribed LDN between 2022 and 2023 were reviewed.
Managing Burning Mouth Syndrome: Current and Future Directions.
Drugs
September 2025
Division of Oral Diagnosis, Oral Medicine, and Oral Radiology, College of Dentistry, University of Kentucky, Lexington, KY, USA.
Burning mouth syndrome (BMS) is a chronic pain condition characterized by a persistent burning sensation in the oral mucosa in the absence of visible clinical signs. Its management remains a significant clinical challenge due to the unclear and multifactorial nature of its etiopathogenesis. Differentiating between primary (idiopathic) and secondary (associated with identifiable underlying conditions) BMS is critical for guiding treatment.
View Article and Find Full Text PDFTop 20 Research Studies of 2024 for Primary Care Physicians.
Am Fam Physician
July 2025
Michigan State University, East Lansing.
This article summarizes the top 20 research studies of 2024 identified as POEMs (patient-oriented evidence that matters). Based on a network meta-analysis, the oral antibiotics most likely to be effective for community-acquired pneumonia are telithromycin (not available in the United States), azithromycin, amoxicillin-clavulanate, and the quinolones levofloxacin and nemonoxacin (not available in the United States). The oral antivirals molnupiravir and nirmatrelvir-ritonavir reduce hospitalizations in immunocompromised patients with COVID-19.
View Article and Find Full Text PDF